Literature DB >> 28187230

A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment.

Gaelle Saint-Hilary1, Stephanie Cadour2, Veronique Robert2, Mauro Gasparini1.   

Abstract

Quantitative methodologies have been proposed to support decision making in drug development and monitoring. In particular, multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) are useful tools to assess the benefit-risk ratio of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision makers regarding the relative importance of these criteria. However, even in its probabilistic form, MCDA requires the exact elicitations of the weights of the criteria by the decision makers, which may be difficult to achieve in practice. SMAA allows for more flexibility and can be used with unknown or partially known preferences, but it is less popular due to its increased complexity and the high degree of uncertainty in its results. In this paper, we propose a simple model as a generalization of MCDA and SMAA, by applying a Dirichlet distribution to the weights of the criteria and by making its parameters vary. This unique model permits to fit both MCDA and SMAA, and allows for a more extended exploration of the benefit-risk assessment of treatments. The precision of its results depends on the precision parameter of the Dirichlet distribution, which could be naturally interpreted as the strength of confidence of the decision makers in their elicitation of preferences.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Benefit-risk; Decision making; Dirichlet distribution; Multicriteria decision analysis; Stochastic multicriteria acceptability analysis

Mesh:

Year:  2017        PMID: 28187230     DOI: 10.1002/bimj.201600113

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  6 in total

1.  Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis.

Authors:  Kan Li; Shuai Sammy Yuan; William Wang; Shuyan Sabrina Wan; Paulette Ceesay; Joseph F Heyse; Shahrul Mt-Isa; Sheng Luo
Journal:  Contemp Clin Trials       Date:  2018-03-02       Impact factor: 2.226

2.  A Bayesian approach for individual-level drug benefit-risk assessment.

Authors:  Kan Li; Sheng Luo; Sammy Yuan; Shahrul Mt-Isa
Journal:  Stat Med       Date:  2019-04-15       Impact factor: 2.373

3.  A novel measure of drug benefit-risk assessment based on Scale Loss Score.

Authors:  Gaelle Saint-Hilary; Veronique Robert; Mauro Gasparini; Thomas Jaki; Pavel Mozgunov
Journal:  Stat Methods Med Res       Date:  2018-07-20       Impact factor: 3.021

4.  A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints.

Authors:  Pavel Mozgunov; Thomas Jaki
Journal:  Biom J       Date:  2019-07-12       Impact factor: 2.207

5.  A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit-risk assessment.

Authors:  Tom Menzies; Gaelle Saint-Hilary; Pavel Mozgunov
Journal:  Stat Methods Med Res       Date:  2022-01-19       Impact factor: 3.021

6.  From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs.

Authors:  Tommi Tervonen; Francesco Pignatti; Douwe Postmus
Journal:  Med Decis Making       Date:  2019-09-09       Impact factor: 2.583

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.